Patrick  Mercer net worth and biography

Patrick Mercer Biography and Net Worth

CEO of IRIDEX

Mr. Mercer serves as our Chief Operating Officer.  He joined the Company in 2018, bringing over 20 years of experience serving in multiple operational positions across various fields of the medical device industry. Prior to joining IRIDEX,  he was Chief Operating Officer of Tracknet, a privately held LoRaWAN Internet of Things (IoT) solutions provider .  Mr. Mercer also held leadership roles at privately held RODO Medical and DFINE. His global experience includes managing manufacturing operations in Hungary, China, Korea, Costa Rica, Germany, and Australia. Mr. Mercer graduated from the University of Alabama with a BSEE in Electrical Engineering / Computer Engineering.  He also proudly served in the elite Nuclear Power Program for the US Navy.

What is Patrick Mercer's net worth?

The estimated net worth of Patrick Mercer is at least $275.35 thousand as of June 13th, 2025. Mercer owns 386,730 shares of IRIDEX stock worth more than $275,352 as of October 6th. This net worth approximation does not reflect any other assets that Mercer may own. Learn More about Patrick Mercer's net worth.

How do I contact Patrick Mercer?

The corporate mailing address for Mercer and other IRIDEX executives is 1212 Terra Bella Ave, Mountain View, CA, 94043. IRIDEX can also be reached via phone at (650) 940-4700 and via email at [email protected]. Learn More on Patrick Mercer's contact information.

Has Patrick Mercer been buying or selling shares of IRIDEX?

Patrick Mercer has not been actively trading shares of IRIDEX in the last ninety days. Most recently, on Friday, June 13th, Patrick Mercer bought 250 shares of IRIDEX stock. The stock was acquired at an average cost of $0.96 per share, with a total value of $240.00. Following the completion of the transaction, the chief executive officer now directly owns 386,730 shares of the company's stock, valued at $371,260.80. Learn More on Patrick Mercer's trading history.

Who are IRIDEX's active insiders?

IRIDEX's insider roster includes Nandini Devi (Director), Robert Grove (Director), Beverly Huss (Director), and Patrick Mercer (CEO). Learn More on IRIDEX's active insiders.

Are insiders buying or selling shares of IRIDEX?

In the last year, IRIDEX insiders bought shares 2 times. They purchased a total of 50,000 shares worth more than $48,500.00. The most recent insider tranaction occured on November, 17th when Director William M Moore bought 21,843 shares worth more than $21,187.71. Insiders at IRIDEX own 8.6% of the company. Learn More about insider trades at IRIDEX.

Information on this page was last updated on 11/17/2025.

Patrick Mercer Insider Trading History at IRIDEX

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
6/13/2025Buy250$0.96$240.00386,730View SEC Filing Icon  
4/28/2025Buy7,500$1.29$9,675.00400,790View SEC Filing Icon  
4/24/2025Buy46$1.15$52.90393,290View SEC Filing Icon  
See Full Table

Patrick Mercer Buying and Selling Activity at IRIDEX

This chart shows Patrick Mercer's buying and selling at IRIDEX by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

IRIDEX Company Overview

IRIDEX logo
IRIDEX Corporation, an ophthalmic medical technology company, provides therapeutic based laser systems, delivery devices, and consumable instrumentation to treat sight-threatening eye diseases in ophthalmology. It offers laser consoles, such as Cyclo G6 laser system for use in the treatment of glaucoma; IQ 532 and IQ 577 laser systems, which are used for the treatment of retinal disorders; and OcuLight TX, OcuLight SL, OcuLight SLx, OcuLight GL, and OcuLight GLx laser photocoagulation systems that are used to treat proliferative diabetic retinopathy, macular holes, retinal tears, and detachments. The company also provides delivery devices, including TxCell scanning laser delivery system that allows the physician to perform multi-spot pattern scanning; slit lamp adapter, which allows the physician to utilize a standard slit lamp in diagnosis and treatment procedures; and laser indirect ophthalmoscope for use in procedures to treat peripheral retinal disorders. It offers MicroPulse P3 Probe, which is used with its Cylco G6 laser system to perform MicroPulse transscleral laser therapy; G-Probe, which is used in procedures to treat uncontrolled glaucoma; G-Probe and G-Probe Illuminate, which are used in procedures to treat refractory glaucoma; and EndoProbe family of products for use in vitrectomy procedures. The company serves ophthalmologists, research and teaching hospitals, government installations, surgical centers, hospitals, veterinary practices, and office clinics. It markets its products through direct and independent sales force in the United States, as well as through independent distributors internationally. The company was formerly known as IRIS Medical Instruments, Inc. and changed its name to IRIDEX Corporation in November 1995. IRIDEX Corporation was incorporated in 1989 and is headquartered in Mountain View, California.
Read More

Today's Range

Now: $0.70
Low: $0.70
High: $0.73

50 Day Range

MA: $0.73
Low: $0.61
High: $0.93

2 Week Range

Now: $0.70
Low: $0.61
High: $1.65

Volume

14,705 shs

Average Volume

133,851 shs

Market Capitalization

$12.21 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.67